Contact Us

The choice depends on whether you are studying CASP6's role as a tertiary executioner caspase or modeling its emerging functions in Huntington's disease and neurodegeneration. The Knockout line is the standard tool for asking whether CASP6 is required for these processes — CASP6 (caspase-6) is an executioner caspase (with CASP3, CASP7) that cleaves substrates downstream of initiator caspases; CASP6 has emerged as particularly relevant in neurodegeneration through cleavage of huntingtin (HTT) at D586 generating neurotoxic N-terminal fragments — D586A mutation in HTT confers neuroprotection in Huntington's disease models. Overexpression is useful for studying CASP6 gain-of-function effects. Important consideration: CASP3, CASP7 paralog expression analysis aids interpretation given partial substrate overlap. Rescue with wild-type or catalytically-dead CASP6 (C163S) is the standard specificity control. The knockout is valuable for studying executioner caspase biology, HTT proteolytic cleavage in Huntington's disease, and emerging CASP6-targeted therapeutic approaches for neurodegeneration.

Yes. CASP6 rescue experiments require attention to executioner caspase architecture: • Construct design: use a codon-modified CASP6 sequence with a small C-terminal tag (FLAG, HA). CASP6 has the canonical caspase prodomain-large subunit-small subunit architecture with catalytic C163 — preserve all elements. • Catalytically-dead rescue: C163S mutation in the catalytic cysteine abolishes proteolytic activity. • Auto-processing-deficient rescue: cleavage site mutations affect CASP6 maturation. • Functional readout: rescue should restore CASP6 substrate (HTT D586, lamin A/C) cleavage. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying BCHE (butyrylcholinesterase, pseudocholinesterase)'s role as the principal hepatic serum cholinesterase or modeling its applications in toxicology and emerging therapeutic uses. The Knockout line is the standard tool for asking whether BCHE is required for these processes — BCHE is a serum esterase (synthesized in liver, secreted into serum) closely related to acetylcholinesterase (AChE); BCHE hydrolyzes choline esters with broad substrate specificity, including succinylcholine (suxamethonium) — patients with BCHE deficiency experience prolonged neuromuscular blockade with this anesthetic; BCHE also hydrolyzes cocaine, mivacurium, and is an emerging therapy for cocaine overdose and organophosphate poisoning. Overexpression is useful for studying BCHE gain-of-function effects. For pharmacology and toxicology research, the EDITGENE BCHE Knockout in HAP1 enables study of BCHE biology. Rescue with wild-type, catalytically-dead, or 'atypical' (D70G — pseudocholinesterase deficiency variant causing suxamethonium sensitivity) BCHE enables structure-function studies. The knockout is valuable for studying BCHE biology, pseudocholinesterase deficiency, cocaine pharmacology (BCHE-based cocaine hydrolysis therapy), and emerging BCHE-based organophosphate antidote development.

Yes. BCHE rescue experiments require attention to secreted enzyme processing: • Construct design: use a codon-modified BCHE sequence with a small N-terminal tag (FLAG, HA, after signal peptide) — BCHE is a secreted enzyme processed from a signal peptide-containing precursor; C-terminal tag may affect secretion or tetramerization. • Secretion validation: confirm conditioned media BCHE activity by butyrylthiocholine hydrolysis. • Catalytically-dead rescue: S198A in the catalytic serine triad abolishes esterase activity. • Atypical variant rescue: D70G atypical variant enables pseudocholinesterase deficiency modeling. • Functional readout: rescue should restore butyrylcholine hydrolysis activity. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CASK (calcium/calmodulin-dependent serine protein kinase)'s role as a MAGUK scaffold protein or modeling its functions in MICPCH syndrome and FG syndrome 4. The Knockout line is the standard tool for asking whether CASK is required for these processes — CASK is an unusual MAGUK family member with N-terminal CaMKII-like kinase domain (Mg²⁺-independent kinase activity), L27 domains, PDZ, SH3, and GUK domains; CASK scaffolds synaptic and epithelial junction complexes, binds neurexin and SAP97; CASK has reported atypical kinase activity that does not require Mg²⁺. Overexpression is useful for studying CASK in heterologous expression contexts. For neurodevelopmental disease research, the EDITGENE CASK Knockout in HAP1 is highly informative — CASK X-linked mutations cause microcephaly with pontine and cerebellar hypoplasia (MICPCH; OMIM 300749) and FG syndrome 4 (FGS4; intellectual disability syndrome). Rescue with wild-type or kinase-dead CASK enables structure-function studies. The knockout is valuable for studying MAGUK scaffold biology, synaptic complex assembly, and emerging CASK-related neurodevelopmental disorder mechanisms.

Yes. CASK rescue experiments require attention to MAGUK scaffold architecture: • Construct design: use a codon-modified CASK sequence with a small C-terminal tag (FLAG, HA). CASK has N-terminal CaMKII-like kinase domain, two L27 domains, PDZ, SH3, and GUK domains — preserve all elements. • Kinase-dead rescue: D146A or kinase domain catalytic residue mutations abolish CASK's unusual Mg²⁺-independent kinase activity. • PDZ-mutant rescue: PDZ domain mutations disrupt neurexin and other PDZ-binding-motif interactions. • MICPCH/FG syndrome mutation rescue: patient-derived CASK mutations enable disease genotype-function studies. • Functional readout: rescue should restore MAGUK scaffold assembly with neurexin and SAP97. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CDKL5 (cyclin-dependent kinase-like 5, STK9)'s role as a CMGC-family kinase or modeling CDKL5 deficiency disorder (CDD, a severe neurodevelopmental encephalopathy). The Knockout line is the standard tool for asking whether CDKL5 is required for these processes — CDKL5 is a serine/threonine kinase with sequence similarity to MAPKs and CDKs but distinct substrate specificity, with characterized substrates including EB2 (microtubule plus-end protein), MAP1S, NDE1, AMPH1; CDKL5 has roles in dendritic spine maturation and synaptic function. Overexpression is useful for studying CDKL5 gain-of-function effects. For neurodevelopmental disease research, the EDITGENE CDKL5 Knockout in HAP1 enables study of CDKL5 biology. CDKL5 X-linked mutations cause CDKL5 deficiency disorder (CDD, formerly atypical Rett syndrome), a severe early-onset epileptic encephalopathy with intellectual disability. Rescue with wild-type, kinase-dead, or patient-derived CDKL5 mutations enables disease genotype-function studies. The knockout is valuable for studying CDKL5 biology and emerging CDKL5-targeted approaches including gene therapy (the CDKL5 gene therapy programs are in preclinical/early clinical development); ⭐ ganaxolone (Ztalmy) — FDA-approved 2022 for CDD seizures — does not directly target CDKL5 but addresses the disease symptom.

Yes. CDKL5 rescue experiments are critical for CDD gene therapy research: • Construct design: use a codon-modified CDKL5 sequence with a small C-terminal tag (FLAG, HA). CDKL5 has N-terminal kinase domain and C-terminal regulatory tail — preserve all elements. • Kinase-dead rescue: K42R mutation in the ATP-binding lysine abolishes catalytic activity. • CDD patient mutation rescue: kinase domain missense mutations (R59X, R134X, others) and C-terminal truncation mutations enable disease genotype-function studies. • Gene therapy validation: rescue with codon-optimized CDKL5 supports preclinical gene therapy vector validation. • Functional readout: rescue should restore CDKL5 substrate phosphorylation (phospho-EB2, phospho-MAP1S). HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying ASXL1 (additional sex combs like 1)'s role as a Polycomb-related epigenetic regulator or modeling ASXL1-mutated MDS/AML and Bohring-Opitz syndrome. The Knockout line is the standard tool for asking whether ASXL1 is required for these processes — ASXL1 is a member of the PR-DUB (Polycomb repressive deubiquitinase) complex with BAP1, deubiquitinating H2AK119ub (the PRC1 mark); ASXL1 has emerged as one of the most frequently mutated genes in MDS, AML, and CHIP (clonal hematopoiesis of indeterminate potential), typically as truncating mutations generating gain-of-function ASXL1 fragments. Overexpression is useful for studying ASXL1 gain-of-function effects. For hematologic malignancy research, the EDITGENE ASXL1 Knockout in OCI-AML3 is uniquely valuable — OCI-AML3 is an NPM1c/DNMT3A R882C-mutant AML cell line, providing a clinically representative AML context. Rescue with wild-type or truncating ASXL1 mutants (Y591X, R693X, others) enables disease modeling — these truncations are characteristic of MDS/AML and confer dominant gain-of-function. ASXL1 de novo missense mutations cause Bohring-Opitz syndrome. The knockout is valuable for studying H2AK119ub epigenetic regulation, CHIP biology, and emerging AML therapy approaches in ASXL1-mutated contexts.

Yes, with critical considerations for ASXL1's dominant gain-of-function truncation biology: • Construct design: use a codon-modified ASXL1 sequence with a small C-terminal tag (FLAG, HA). ASXL1 has N-terminal HARE-HTH and ASXM domains, central PHD finger, and C-terminal PHD finger — preserve all elements for full-length rescue. • Truncating mutation rescue: ⭐⭐ Y591X, R693X, G646Wfs*12, and other patient-derived truncations enable disease modeling — these truncations confer dominant gain-of-function, recruiting BAP1 to inappropriate genomic sites. • ASXM-mutant rescue: ASXM domain mutations affect BAP1 interaction. • Functional readout: rescue should restore H2AK119ub levels and PR-DUB complex function; truncating mutants should recapitulate disease-associated H2AK119ub redistribution. OCI-AML3-specific considerations: • OCI-AML3 is a human acute myeloid leukemia cell line with two clinically important mutations: NPM1 type A mutation (NPM1c, cytoplasmic mislocalization) and DNMT3A R882C — making it one of the most clinically representative AML cell lines. • Lentiviral transduction is supported with moderate efficiency. • OCI-AML3's mutation profile is relevant for studying NPM1c AML biology and emerging menin-MLL inhibitor (revumenib/SNDX-5613, ziftomenib/KO-539) targeted therapy.

The choice depends on whether you are studying AIM2 (absent in melanoma 2)'s role as a cytoplasmic dsDNA sensor and inflammasome scaffold or modeling its functions in innate immunity and emerging cancer applications. The Knockout line is the standard tool for asking whether AIM2 is required for these processes — AIM2 is a HIN-200 family cytoplasmic dsDNA sensor that detects bacterial, viral, and host genomic dsDNA, oligomerizing to assemble the AIM2 inflammasome with ASC/PYCARD and pro-caspase-1; AIM2 inflammasome activation drives IL-1β/IL-18 maturation and gasdermin D-mediated pyroptosis. Overexpression is useful for studying AIM2 gain-of-function effects. For innate immunity research, the EDITGENE Aim2 Knockout in IBMDM is highly relevant — IBMDM is an immortalized murine BMDM line, providing a physiologically relevant macrophage context for inflammasome research. Other AIM2-like receptors (IFI16, etc.) expression analysis aids interpretation. Rescue with wild-type or DNA-binding-deficient (HIN domain mutations) AIM2 enables structure-function studies. The knockout is valuable for studying cytoplasmic dsDNA sensing, AIM2 inflammasome biology in intracellular bacterial infections (Francisella, Listeria, Mycobacterium), and emerging AIM2 functions in cancer biology and DNA damage response.

Yes. AIM2 rescue experiments are well-established for inflammasome research: • Construct design: use a codon-modified Aim2 sequence with a small C-terminal tag (FLAG, HA). AIM2 has N-terminal PYD (pyrin) domain (ASC binding) and C-terminal HIN-200 domain (dsDNA binding) — preserve all elements. • DNA-binding-deficient rescue: HIN domain mutations abolish dsDNA binding. • PYD-mutant rescue: PYD domain mutations disrupt ASC interaction. • Functional readout: rescue should restore dsDNA-induced inflammasome activation, IL-1β maturation, and ASC speck formation. IBMDM-specific considerations: • IBMDM is an immortalized murine bone marrow-derived macrophage cell line, providing a renewable myeloid context for innate immunity and inflammasome research. • Lentiviral transduction is supported with moderate efficiency. • Macrophage activation (LPS, IFN-γ priming) should be characterized before inflammasome and antimicrobial response assays.

The choice depends on whether you are studying CPT1A (carnitine palmitoyltransferase 1A)'s role as the rate-limiting enzyme of long-chain fatty acid β-oxidation or modeling CPT1A deficiency and emerging cancer metabolism applications. The Knockout line is the standard tool for asking whether CPT1A is required for these processes — CPT1A catalyzes the conjugation of long-chain acyl-CoA with carnitine on the outer mitochondrial membrane, generating long-chain acylcarnitine that can be translocated into mitochondria via CACT (SLC25A20) for β-oxidation; CPT1A is the liver/most-tissue isoform (CPT1B is muscle-specific, CPT1C is brain). CPT1A is inhibited by malonyl-CoA (the first intermediate of fatty acid synthesis), providing reciprocal regulation of lipid oxidation and synthesis. Overexpression is useful for studying CPT1A gain-of-function effects. For fatty acid metabolism research, the EDITGENE CPT1A Knockout in HAP1 enables study of long-chain FAO biology. CPT1A biallelic loss-of-function causes CPT1A deficiency (autosomal recessive disorder of FAO with hepatic encephalopathy, hypoglycemia); a CPT1A P479L variant is common in Arctic Inuit populations. Rescue with wild-type, catalytically-dead, or malonyl-CoA-insensitive (M593S, M593G — malonyl-CoA-resistant CPT1A) enables structure-function studies. The knockout is a critical specificity control for etomoxir (CPT1A inhibitor used in metabolic research and as a tool compound), perhexiline (FDA-approved anti-anginal), and emerging CPT1A-targeted therapeutics in cancer (CPT1A is upregulated in many cancers as a fatty acid oxidation dependency).

Yes. CPT1A rescue experiments require attention to mitochondrial outer membrane targeting: • Construct design: use a codon-modified CPT1A sequence with a small C-terminal tag (FLAG, HA). CPT1A has N-terminal mitochondrial outer membrane targeting (two transmembrane spans), central catalytic domain (acyltransferase activity), and C-terminal regions including malonyl-CoA binding site — preserve all elements. • Mitochondrial outer membrane localization validation: confirm MOM localization before functional assays. • Catalytically-dead rescue: His473 or other catalytic residue mutations abolish acyltransferase activity. • Malonyl-CoA-insensitive rescue: M593S or M593G mutations generate malonyl-CoA-resistant CPT1A, enabling separation of FAO regulation by malonyl-CoA from catalytic activity. • Patient mutation rescue: P479L (Arctic Inuit) and other patient-derived CPT1A mutations enable disease genotype-function studies. • Functional readout: rescue should restore long-chain FAO measured by ¹⁴C-palmitate oxidation. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CMAS (cytidine monophosphate N-acetylneuraminic acid synthetase, CMP-Neu5Ac synthase)'s role as the principal sialic acid activation enzyme or modeling its functions in sialic acid-dependent glycobiology. The Knockout line is the standard tool for asking whether CMAS is required for these processes — CMAS catalyzes the activation of N-acetylneuraminic acid (Neu5Ac) to CMP-Neu5Ac, the donor substrate for all sialyltransferases that add sialic acid to glycoproteins, glycolipids, and gangliosides; CMAS is the obligate enzyme for sialylation, making it a central player in glycobiology. Overexpression is useful for studying CMAS in heterologous expression contexts. For glycobiology research, the EDITGENE CMAS Knockout in HAP1 is highly informative — CMAS loss eliminates virtually all cellular sialylation, generating an asialo cellular surface; CMAS biallelic loss-of-function mutations cause a congenital disorder of glycosylation with developmental delay. Rescue with wild-type or catalytically-dead CMAS enables structure-function studies. The knockout is a critical specificity tool for studying sialic acid-dependent processes (Siglec receptor recognition, viral entry, cell-cell interaction) and emerging glycobiology research.